NIA‐AA research framework: toward a biological definition of Alzheimer's disease
CR Jack Jr, DA Bennett, K Blennow… - Alzheimer's & …, 2018 - Wiley Online Library
Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …
[HTML][HTML] Biomarker modeling of Alzheimer's disease
CR Jack, DM Holtzman - Neuron, 2013 - cell.com
Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …
Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
For early detection of Alzheimer's disease, it is important to find biomarkers with predictive
value for disease progression and clinical manifestations, such as cognitive decline …
value for disease progression and clinical manifestations, such as cognitive decline …
Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation
Amyloid-β, a hallmark of Alzheimer's disease, begins accumulating up to two decades
before the onset of dementia, and can be detected in vivo applying amyloid-β positron …
before the onset of dementia, and can be detected in vivo applying amyloid-β positron …
Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for
which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of …
which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of …
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's …
KA Johnson, S Minoshima, NI Bohnen… - Alzheimer's & …, 2013 - Elsevier
Positron emission tomography (PET) of brain amyloid β is a technology that is becoming
more available, but its clinical utility in medical practice requires careful definition. To …
more available, but its clinical utility in medical practice requires careful definition. To …
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
CR Jack Jr, HJ Wiste, H Botha, SD Weigand… - Brain, 2019 - academic.oup.com
Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …
recently come into existence. Our objective was to determine relationships between the …
Alzheimer's disease
Alzheimer's disease is a chronic illness with long preclinical and prodromal phases (20
years) and an average clinical duration of 8–10 years. The disease has an estimated …
years) and an average clinical duration of 8–10 years. The disease has an estimated …
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ (1–42), pTau and tTau CSF immunoassays
K Blennow, LM Shaw, E Stomrud, N Mattsson… - Scientific reports, 2019 - nature.com
We evaluated the performance of CSF biomarkers for predicting risk of clinical decline and
conversion to dementia in non-demented patients with cognitive symptoms. CSF samples …
conversion to dementia in non-demented patients with cognitive symptoms. CSF samples …
Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection
Alzheimer's disease is a progressive neurodegenerative disease that typically manifests
clinically as an isolated amnestic deficit that progresses to a characteristic dementia …
clinically as an isolated amnestic deficit that progresses to a characteristic dementia …